177 related articles for article (PubMed ID: 37936709)
41. Longitudinal Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Antibody Responses and Identification of Vaccine Breakthrough Infections Among Healthcare Workers Using Nucleocapsid Immunoglobulin G.
Anderson M; Stec M; Gosha A; Mohammad T; Boler M; Tojo Suarez R; Behun D; Landay A; Cloherty G; Moy J
J Infect Dis; 2022 Nov; 226(11):1934-1942. PubMed ID: 36263799
[TBL] [Abstract][Full Text] [Related]
42. Correlates of protection against COVID-19 infection and intensity of symptomatic disease in vaccinated individuals exposed to SARS-CoV-2 in households in Israel (ICoFS): a prospective cohort study.
Regev-Yochay G; Lustig Y; Joseph G; Gilboa M; Barda N; Gens I; Indenbaum V; Halpern O; Katz-Likvornik S; Levin T; Kanaaneh Y; Asraf K; Amit S; Rubin C; Ziv A; Koren R; Mandelboim M; Tokayer NH; Meltzer L; Doolman R; Mendelson E; Alroy-Preis S; Kreiss Y
Lancet Microbe; 2023 May; 4(5):e309-e318. PubMed ID: 36963419
[TBL] [Abstract][Full Text] [Related]
43. Humoral response to COVID-19 vaccination in MS patients on disease modifying therapy: Immune profiles and clinical outcomes.
Holroyd KB; Healy BC; Conway S; Houtchens M; Bakshi R; Bhattacharyya S; Bose G; Galetta K; Kaplan T; Severson C; Singhal T; Stazzone L; Zurawski J; Polgar-Turcsanyi M; Saxena S; Paul A; Glanz BI; Weiner HL; Chitnis T
Mult Scler Relat Disord; 2022 Nov; 67():104079. PubMed ID: 35952457
[TBL] [Abstract][Full Text] [Related]
44. Dynamic changes in lymphocyte subsets and parallel cytokine levels in patients with severe and critical COVID-19.
Liu Y; Tan W; Chen H; Zhu Y; Wan L; Jiang K; Guo Y; Tang K; Xie C; Yi H; Kuang Y; Luo Y
BMC Infect Dis; 2021 Jan; 21(1):79. PubMed ID: 33461503
[TBL] [Abstract][Full Text] [Related]
45. Longitudinal Follow-Up of the Immunity to SARS-CoV-2 in Health Care Workers in Argentina: Persistence of Humoral Response and Neutralizing Capacity after Sputnik V Vaccination.
Castro EF; Acosta J; Moriena L; Rios Medrano M; Tejerina Cibello M; Codino E; Taborda MÁ; Álvarez DE; Cavatorta AL
mSphere; 2023 Jun; 8(3):e0066222. PubMed ID: 37070983
[TBL] [Abstract][Full Text] [Related]
46. Neutralizing Antibody Responses against Five SARS-CoV-2 Variants and T Lymphocyte Change after Vaccine Breakthrough Infections from the SARS-CoV-2 Omicron BA.1 Variant in Tianjin, China: A Prospective Study.
Zhang Y; Qu JW; Zheng MN; Ding YX; Chen W; Ye SD; Li XY; Li YK; Liu Y; Zhu D; Jin CR; Wang L; Yang JY; Zhai Y; Wang EQ; Meng X
Biomed Environ Sci; 2023 Jul; 36(7):614-624. PubMed ID: 37533385
[TBL] [Abstract][Full Text] [Related]
47. The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial.
Chaccour C; Ruiz-Castillo P; Richardson MA; Moncunill G; Casellas A; Carmona-Torre F; Giráldez M; Mota JS; Yuste JR; Azanza JR; Fernández M; Reina G; Dobaño C; Brew J; Sadaba B; Hammann F; Rabinovich R
Trials; 2020 Jun; 21(1):498. PubMed ID: 32513289
[TBL] [Abstract][Full Text] [Related]
48. Comparison of humoral and cellular immune responses between ChAd-BNT heterologous vaccination and BNT-BNT homologous vaccination following the third BNT dose: A prospective cohort study.
Sim W; Kang H; Jung J; Lee J; Ko GY; Park HS; Choi J; Park K; Oh EJ
Front Immunol; 2023; 14():1120556. PubMed ID: 36936965
[TBL] [Abstract][Full Text] [Related]
49. Detection of IgM, IgG, IgA and neutralizing antibody responses to SARS-CoV-2 infection and mRNA vaccination.
Fleischmann CJ; Bulman CA; Yun C; Lynch KL; Wu AHB; Whitman JD
J Med Microbiol; 2023 Jan; 72(1):. PubMed ID: 36748419
[No Abstract] [Full Text] [Related]
50. Influence of Aerosol Delivered BCG Vaccination on Immunological and Disease Parameters Following SARS-CoV-2 Challenge in Rhesus Macaques.
White AD; Sibley L; Sarfas C; Morrison AL; Bewley K; Churchward C; Fotheringham S; Gkolfinos K; Gooch K; Handley A; Humphries HE; Hunter L; Kennard C; Longet S; Mabbutt A; Moffatt M; Rayner E; Tipton T; Watson R; Hall Y; Bodman-Smith M; Gleeson F; Dennis M; Salguero FJ; Carroll M; McShane H; Cookson W; Hopkin J; Sharpe S
Front Immunol; 2021; 12():801799. PubMed ID: 35222355
[TBL] [Abstract][Full Text] [Related]
51. Nutritional risk and a high NRS2002 score are closely related to disease progression and poor prognosis in patients with COVID-19.
Zhou Y; Chen Y; Zhang X; Zhao B; Gao F; Yuan X; Zhu Y; Liu D
Front Nutr; 2023; 10():1089972. PubMed ID: 37125047
[TBL] [Abstract][Full Text] [Related]
52. Cellular immune response to SARS-CoV-2 in patients with primary antibody deficiencies.
Mizera D; Dziedzic R; Drynda A; Gradzikiewicz A; Jakieła B; Celińska-Löwenhoff M; Padjas A; Matyja-Bednarczyk A; Zaręba L; Bazan-Socha S
Front Immunol; 2023; 14():1275892. PubMed ID: 37901210
[TBL] [Abstract][Full Text] [Related]
53. Unveiling a New Perspective on Distinguishing Omicron Breakthrough Cases and Postimmune COVID-19-Naive Individuals: Insights from Antibody Profiles.
Zhang S; Dong C; Zhen Q; Shi C; Tian H; Li C; Kong X; Dai Q; Huang H; Simayi A; Zhu F; Xu Y; Hu J; Xu K; Chen L; Bao C; Jin H; Zhu L
Microbiol Spectr; 2023 Aug; 11(4):e0180823. PubMed ID: 37432106
[TBL] [Abstract][Full Text] [Related]
54. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
55. Immune response to the third COVID-19 vaccine dose is related to lymphocyte count in multiple sclerosis patients treated with fingolimod.
Achiron A; Mandel M; Gurevich M; Dreyer-Alster S; Magalashvili D; Sonis P; Dolev M; Menascu S; Harari G; Flechter S; Falb R
J Neurol; 2022 May; 269(5):2286-2292. PubMed ID: 35235002
[TBL] [Abstract][Full Text] [Related]
56. Subjects who developed SARS-CoV-2 specific IgM after vaccination show a longer humoral immunity and a lower frequency of infection.
Piubelli C; Ruggiero A; Calciano L; Mazzi C; Castilletti C; Tiberti N; Caldrer S; Verzè M; Longoni SS; Accordini S; Bisoffi Z; Zipeto D
EBioMedicine; 2023 Mar; 89():104471. PubMed ID: 36796232
[TBL] [Abstract][Full Text] [Related]
57. Immune Responses to SARS-CoV-2 Vaccination in Young Patients with Anti-CD19 Chimeric Antigen Receptor T Cell-Induced B Cell Aplasia.
Jarisch A; Wiercinska E; Huenecke S; Bremm M; Cappel C; Hauler J; Rettinger E; Soerensen J; Hellstern H; Klusmann JH; Ciesek S; Bonig H; Bader P
Transplant Cell Ther; 2022 Jul; 28(7):366.e1-366.e7. PubMed ID: 35472554
[TBL] [Abstract][Full Text] [Related]
58. Severe acute respiratory syndrome coronavirus 2 serology levels in pregnant women and their neonates.
Kubiak JM; Murphy EA; Yee J; Cagino KA; Friedlander RL; Glynn SM; Matthews KC; Jurkiewicz M; Sukhu AC; Zhao Z; Prabhu M; Riley LE; Yang YJ
Am J Obstet Gynecol; 2021 Jul; 225(1):73.e1-73.e7. PubMed ID: 33497654
[TBL] [Abstract][Full Text] [Related]
59. Effect of Third and Fourth mRNA-Based Booster Vaccinations on SARS-CoV-2 Neutralizing Antibody Titer Formation, Risk Factors for Non-Response, and Outcome after SARS-CoV-2 Omicron Breakthrough Infections in Patients on Chronic Hemodialysis: A Prospective Multicenter Cohort Study.
Tillmann FP; Figiel L; Ricken J; Still H; Korte C; Plaßmann G; Harth A; Jörres A; von Landenberg P
J Clin Med; 2022 Jun; 11(11):. PubMed ID: 35683580
[TBL] [Abstract][Full Text] [Related]
60. [Correlation between the early dynamic changes of lymphocyte and severity of disease in coronavirus disease 2019 patients].
Zhou J; Zhou Y; Cai J; Lin S
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2021 Aug; 33(8):922-926. PubMed ID: 34590557
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]